Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Simulations Plus Inc SLP

Healthcare Medical Devices

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The Company’s comprehensive bio simulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. It operates through two segments: software and services. It offers software products for pharmaceutical research, development, and commercialization, including GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym and others. In addition, it also delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development.

NDAQ:SLP - Post by User

Simulations Plus Inc

Bullboard Posts

Next >>

Post by Betteryear2on Apr 03, 2024 5:28pm

60 Views

Post# 35968982

Simulations Plus Reports Second Quarter Fiscal 2024 Results

April 03, 2024 04:34 PM Eastern Daylight Time

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results | Business Wire